A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors
Latest Information Update: 23 Jun 2025
At a glance
- Drugs SSGJ 709 (Primary)
- Indications Adenocarcinoma; Clear cell sarcoma; Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 23 Jun 2025 New trial record